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Acute generalized exanthematous pustulosis (AGEP) is a rare drug-induced pustular cutaneous reaction. 
The clinical course is characteristic with a sudden onset of multiple sterile pustules on an erythemantous 
base with fever and neutrophilia, followed by a spontaneous resolution within two weeks. Drug-specific T 
cells play the main role in the pathogenesis, but the exact cytokine cascade and genetic background are yet 
to be elucidated. Timely and exact recognition is important in order to prevent confusion with infections 
and psoriasis and hence institution of unnecessary and wrong treatments. The diagnosis may be confirmed 
by typical history, identification of a culprit drug, histopathology and patch testing. The purpose of this re-
view is to present the current knowledge on AGEP and its association with various drugs in the context of a 
drug allergic reaction.
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INTRODUCTION
AGEP is a rare self-limiting pustular cutaneous 
reaction, most commonly triggered by intake of cer-
tain drugs. Its characteristic clinical findings with 
acute development of pustular rash and fever along 
with a typical histology allow for a timely diagnosis 
and proper management. 
The term acute generalized exanthematous 
pustulosis was first compiled by Beylot et al. in 1980 
(1). This name is now widely used for this character-
istic reaction pattern, although the disease has been 
given numerous other labels in the medical literature 
such as toxic pustuloderma, pustular drug rash and 
pustular psoriasiform eruption with leucocytosis (2). 
Epidemiology
The estimated incidence of AGEP ranges from 
one to five cases per million people per year (3). The 
actual incidence is most probably higher taking into 
account the reporting under different names in the 
literature, the low level of spontaneous drug reactions 
reporting and the transient nature of the disease. 
Any age could be affected and childhood occurrence 
has also been described (4,5). Female predisposition 
has recently been suggested (3,6) and this trend 
is consistent with the general trend for female 
predominance in drug reactions (7). Seasonality has 
also been reported in one study with a case series of 
patients developing the disease during the summer 
months (3).
Pathogenesis
AGEP is a drug-induced reaction mediated by 
drug-specific T-cells (CD4+ and CD8+) and interleu-
kin (IL)-8. IL-8 is responsible for priming, i.e. activa-
tion and recruitment of neutrophils that initiate a neu-
trophil-mediated inflammatory reaction in the skin 
by drug-specific cytotoxicity and by release of inflam-
matory cytokines and chemoattractants such as IL-5, 
interferon-gamma (IFN-γ), granulocyte-macrophage 
colony-stimulating factor (GM-CSF), transforming 
growth factor (TGF-β) and RANTES (8). 
Drug-specific CD4(+) and CD8(+) T cells are 
both cytotoxic and activated to secrete cytokines. T 
cells produce perforin/granzyme B and activate the 
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Fas/FasL-killing mechanism thus allowing the for-
mation of vesicles. IL8-producing T-cells from AGEP 
patients are predominantly Th1-type and secrete 
both factors that attract neutrophils and factors that 
reduce and impede neutrophil apoptosis. Additional 
secretion of IL-8 by T cells and keratinocytes attracts 
neutrophils that fill the vesicles and transform them 
into the sterile pustules of AGEP (9) (10) (11).
Most recent studies suggest a possible involve-
ment of keratynocytic IL-8 and drug-activated Th17 
cells in the pathogenesis of AGEP. Both Th17 cells 
and their main product – IL-22 are found to be el-
evated in patients with AGEP compared to healthy 
controls. The authors speculate that IL-17 and IL-22 
stimulate keratynocytes to produce IL-8 thus induc-
ing the formation of the subcorneal infiltrate of neu-
trophils that is a hallmark of AGEP (12).
Genetic predisposition is also believed to be a 
background for reaction triggering and neutrophil 
shifting but data is still insufficient to postulate a 
pathogenetic role. Bernhard et al. found an enhanced 
expression of HLA B51, DR11 and DQ3 in patients 
with AGEP compared to the average population (13).
Causes and risk factors
AGEP has been attributed to a variety of causes, 
but so far drugs seem to be the main culprit.
Drugs
Enormous number of medications has been re-
ported in the medical literature to cause AGEP, both 
in individual cases and small series. Nevertheless, 
causative drugs for AGEP differ substantially from 
drugs associated with Stevens Johnson syndrome/
toxic epidermal necrolysis (SJS/TEN) or other skin 
drug reactions.
The EuroSCAR study (a multinational case-
control study, including 97 patients with AGEP) 
evaluated the risk for different drugs to cause severe 
cutaneous drug reaction and revealed agents with 
strong and agents with weak association to the dis-
ease. As drugs with high risk to trigger AGEP were 
defined pristinamycin, ampicillin/amoxicillin, qui-
nolones, (hydroxy)chloroquine, sulphonamides, ter-
binafine and diltiazem. Less strong association was 
recorded for corticosteroids, macrolides, non-steroi-
dal anti-inflammatory drugs of the oxicam type and 
antiepileptics (excluding valproic acid) (2). 
Several case reports confirm the causative role 
of systemic corticosteroids by positive exposure, 
withdrawal and patch test results (14,15,16). Other in-
criminated drugs from individual cases or series in-
clude terazosin hydrochloride (17), omeprazole (18), 
sennosides (19), imatinib (20), systemic antifungals 
(21), cefotaxime (22), pseudoephedrine (23), azathi-
oprine (24), cefepime (25), intravitreal ranimizumab 
(26), isotretinoin (27), contrast agents (28), etc.
Time of onset after drug intake is variable and it 
is suggested to be related to the specific drug and its 
mechanism of reaction induction. While most drugs 
require a latent time of 1-2 weeks before AGEP pres-
ents clinically, some other drugs, such as pristina-
mycin and amoxicillin could induce a reaction after 
only one day of intake. The rapid onset might be due 
to a re-challenge after previous exposition to the cul-
prit drug or to another mechanism that has so far not 
been elucidated (2). Longer latent periods have been 
reported in the literature in association with an un-
derlying malignancy (19) (20). 
Infections
Stringent evidence that infections cause AGEP 
are lacking, even though there are case reports as-
sociating AGEP with viral infections, including in-
fections with Parvovirus B19 (29), Cytomegalovirus 
(30), Coxsackie B4 virus (31). Recurrent urinary tract 
infections (32) and Chlamydia pneumoniae (33) have 
also been reported as causative factors for AGEP. 
Nevertheless, the EuroSCAR study did not find any 
significant risk for infection in a multivariate analy-
sis including all 97 validated AGEP cases and 1009 
controls (2). These findings strongly suggest that the 
suspected association of infections with AGEP might 
be due to the anti-infective treatment prescribed to 
treat the disease and not to the very infection. 
Psoriasis
Differential diagnosis between AGEP and pus-
tular psoriasis (PP) is difficult. The clinical and his-
tological presentation, as well as the Ki-67 expression 
(34) of both entities are similar which renders into 
confusion about their differentiation and overlap. Al-
though several cases of AGEP occurred in patients 
with personal or family history of psoriasis, current 
evidence suggests that there is no significant differ-
ence in relation to psoriasis history between AGEP 
patients and healthy controls (2). The slightly high-
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er incidence in the AGEP group could be due to a 
common genetic background that favours neutro-
phil-attracting mechanism in response to triggering 
drugs. Furthermore, many drugs known to exacer-
bate or trigger psoriasis (eg. beta-blockers or angio-
tensin converting enzyme (ACE) inhibitors) have not 
been associated with AGEP.
Other factors
Contact sensitivity. Few cases suggest a role of 
topical agents to induce AGEP through contact sen-
sitivity. Bufexamac, a topical NSAID, induced AGEP 
in an atopic girl and its role was evidenced by a posi-
tive withdrawal and a positive patch test (35). A me-
phenesin-containing topical treatment for muscular 
pain was reported as a causal factor for AGEP in a 51-
year old patient and the sensitivity was further con-
firmed with a positive patch testing (36). 
Spider bites. Role of spider bites was suggested 
in a series of cases and case reports of patients that 
developed AGEP after being bitten by a spider (37). 
The underlying mechanism most probably includes a 
highly increased number of pro-inflammatory cyto-
kines (IL-8 and GM-CSF) by the spider venom with 
subsequent systemic reactions. 
It was recently suggested that AGEP may de-
velop without an apparent causal factor, albeit very 
rarely (38). Indeed, in a series of 63 cases three pa-
tients remained without an elucidated trigger (39). 
Hence, it is very important to still consider the diag-
nosis when presenting with typical clinical and lab-
oratory findings, even when a causative factor could 
not be identified. 
Clinical presentation
The clinical features and clinical course of 
AGEP are characteristic and usually sufficient for an 
initial diagnosis.
AGEP presents with the acute occurrence of oe-
dematous erythema covered by dozens to hundreds 
of pinhead, non-follicular, sterile pustules (Figure 
1). The rash has a predilection for the main folds, 
but widespread distribution is common. Less often 
AGEP could manifest with atypical type of lesions 
including face oedema, purpura, blisters or target-
oid lesions (39) (40). Involvement of mucous mem-
branes is uncommon, usually mild and restricted to 
one body site (most commonly the oral cavity). Sys-
temic symptoms almost always accompany the cu-
taneous manifestations and comprise of fever (above 
38%) and leucocytosis with a neutrophil count of 
more than 7000/µl. Mild eosinophilia has been de-
tected in about one third of patients (39,41).
The clinical course of AGEP is a characteristic 
feature of the disease. Skin symptoms have a sudden 
onset and spontaneous quick resolution. The pus-
tules resolve with a pinpoint desquamation followed 
by a total clearance within several days. Usually the 
episode lasts for up to 15 days when exposure to the 
trigger is discontinued (39,40). Repeated exposure to 
the causative drug results in a recurrence of the dis-
ease (42).
The prognosis is favourable and complications 
are very rare, mostly affecting patients with other 
serious comorbidities. Few case reports of internal 
organ involvement have raised the hypothesis that 
AGEP might be a multi-system disorder (43,44,45) 
but accumulated epidemiologic data does not sup-
port such conclusions. Mortality has been reported 
to be 5% (3).
WORK-UP AND LABORATORY 
FINDINGS
Histopathology
Pustules, sub/intracorneal, intraepidermal or a 
combination of both are found in more than 90% of 
the cases. Although the rash is primarily not follicular, 
in almost one quarter of all patients the pustules show 
follicular distribution. The main epidermal features 
are necrotic keratinocytes and spongiosis with 
neutrophil exocytosis. The main dermal features are 
papillary oedema, mixed superficial, interstitial and 
Fig. 1. Multiple sterile pustules on erythematous 
background
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mid/deep-dermal infiltrates containing neutrophils 
and eosinophils (Figure 2). Characteristic features 
of classical plaque-type psoriasis are infrequent 
and mild. Parakeratosis is the only finding that can 
be observed in more than half of cases, but Munro 
abscesses, suprapapillary plate thinning, tortuous and 
dilated blood vessels and hypogranulosis are rare (41). 
Patch testing
Numerous case reports of AGEP include strong-
ly positive reactions to the culprit drug when patients 
are patch tested. As a type IV, T-cell mediated hyper-
sensitivity reaction, AGEP is suitable for patch test-
ing as, when in contact with skin, drugs are likely 
to elicit a local T-cell response. Drug-specific T cells 
(CD4+ and CD8+) have been isolated and cultured 
from positively reacting patch test sites from patients 
with AGEP (9,46). Nevertheless, results are not in-
variably positive and the limited yield is probably 
due to several factors such as patch test methodolo-
gy, skin barrier function, genetic factors of drug me-
tabolism, drug molecular weight and solubility (47). 
The drugs with the highest frequencies of positive 
patch tests include aromatic anticonvulsants (car-
bamazepine and phenytoin), beta-lactams (especial-
ly amoxycillin) and amino-penicillins, co-trimoxa-
zole, corticosteroids, diltiazem, diazepam, tetraze-
pam and pristinamycin (47). Most of these drugs are 
etiological triggers of AGEP which explains the rela-
tively high percentage of patch test evidenced AGEP 
cases as compared to other drug eruptions. 
Patch testing is so far the only routine test to 
examine a casual relation of AGEP to a suspected 
drug. It is safe and well tolerated and there is only 
one report in the literature so far about a generalized 
AGEP-like reaction following patch testing (48). 
Differential diagnosis
Pustular psoriasis is the entity that most closely 
resembles AGEP and there are still no clear-cut rules 
for differentiation of both diseases, though a set of 
different factors might be used.
Other differential diagnoses to consider include 
subcorneal pustular dermatosis, pustular vasculitis, 
drug hypersensitivity syndrome and Stevens John-
son syndrome/toxic epidermal necrolysis.
Treatment options
As AGEP has a self-limiting nature, most cas-
es do not require management other than withdraw-
al of the culprit drug and supportive care. Systemic 
corticosteroid treatment has been advocated by some 
authors (49) but the potential of corticosteroids to 
cause AGEP must be born in mind. Systemic anti-
pyretics might be considered given they are not sus-
pected as a cause for the occurrence of AGEP.
Several treatments such as etanercept (50) and 
infliximab (51) have been tried in individual cas-
es. TNF-alpha stimulates the inflammation and the 
p53-related apoptosis in AGEP, hence theoretical-
ly TNF-alpha inhibitors may offer and effective and 
fast treatment. Nevertheless, clinical experience with 
these agents is still scarce and their role in the treat-
ment scheme of AGEP remains to be elucidated. 
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